Brief: Aspire Health Science Files Supplemental Motion For Expedited Hearing In Lawsuit Against Hemostemix Inc. And Suspends Patient Recruitment For Hemostemix Cli Phase 2 Clinical Trial
13/02/2020 22:33
Feb 13 (Reuters) - Hemostemix Inc HEM.V :
* ASPIRE HEALTH SCIENCE FILES SUPPLEMENTAL MOTION FOR
EXPEDITED
HEARING IN LAWSUIT AGAINST HEMOSTEMIX INC. AND SUSPENDS PATIENT
RECRUITMENT FOR HEMOSTEMIX CLI PHASE 2 CLINICAL TRIAL
* ASPIRE HEALTH SCIENCE - FILES SUPPLEMENTAL MOTION FOR
EXPEDITED
HEARING IN LAWSUIT AGAINST CO
* ASPIRE HEALTH SCIENCE - SUSPENDS PATIENT RECRUITMENT FOR
HEMOSTEMIX CLI PHASE 2 CLINICAL TRIAL
Source text for Eikon: ID:nCNWllwBpa
Further company coverage: HEM.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hemostemix
See all newsBrief: Hemostemix Announces Financing Update And Secured Convertible Debenture Financing Of Up To $2,000,000
Brief: Aspire Health Science Files Supplemental Motion For Expedited Hearing In Lawsuit Against Hemostemix Inc. And Suspends Patient Recruitment For Hemostemix Cli Phase 2 Clinical Trial
Brief: Aspire Health Sciences Says On Jan 28, 2020, Initiated Legal Proceeding Against Hemostemix Inc
Brief: Hemostemix Announces Private Placement
Brief: Hemostemix Announces Corporate Update